Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2015

View Archived Issues

New models of neurological disorders using genetic manipulation described

Evotec collaborates with Beyond Batten Disease Foundation

Kite Pharma enters into license agreement with the NIH for TCR-based products

HighTide Biopharma starts phase I trial of antidiabetic candidate HTD-4010

Novel PSMA ligand shows promise as a theranostic for prostate cancer

Tofacitinib is beneficial in treating atopic dermatitis in phase IIa study

AFA-19 mitigates neuropathic pain and reduces PTZ-induced seizures in mice

NeoGenomics to acquire Clarient

UT Austin receives Gates Foundation grant to study hu1B7 as pertussis prophylaxis

Takeda initiates phase I study of TAK-831 in development for schizophrenia and cerebellar ataxia

CFFT awards grant to Southern Research to identify drugs for rare CF variants

KemPharm completes intranasal abuse liability trial of KP-201/acetaminophen

Zydus Research Centre presents new anticancer compounds

Model allows testing of fecal microbiota transplantation for Clostridium difficile infection

Glycolysis inhibitor WP-1122 has additional effects on glioblastoma cells

Chugai Pharmaceutical profiles progress of third quarter 2015

Minomic signs agreement enabling clinical trial of cancer imaging agent

Bayer Schering Pharma patents MMP-12 inhibitors

Huabo Biopharm describes new recombinant bifunctional fusion protein

Sanofi develops GDIR agonists

Lupin reports BTK inhibitors

Janssen Pharmaceutica discloses EEF2K and/or PIK3C3 inhibitors

Genvoya noninferior to Stribild in phase III studies in treatment-naive adults with HIV infection

FDA approves Merrimack's liposomal irinotecan for pancreatic cancer

Ocular Therapeutix reports trial results for OTX-TP and Dextenza

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...